Assessing predictors of futility in patients receiving massive transfusions

Assessing predictors of futility in patients receiving massive transfusions - Lo - - Transfusion - Wiley Online Library

Lo, B. D., Merkel, K. R., Dougherty, J. L., Kajstura, T. J., Cruz, N. C., Sikorski, R. A., & Frank, S. M. (2021). Assessing predictors of futility in patients receiving massive transfusions. Transfusion, 10.1111/trf.16410. Advance online publication. https://doi.org/10.1111/trf.16410

Blood Banking Market to witness excellent Long-Term Growth Outlook →

 

HTF MI published a new industry research that focuses on Blood Banking market and delivers in-depth market analysis and future prospects of Global Blood Banking market. The study covers significant data which makes the research document a handy resource for managers, analysts, industry experts and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. The study is segmented by Application/ end users [Hospitals & Blood Center], products type [by Blood Components & by Equipments] and various important geographies like United States, EU, Japan, China, India & Southeast Asia]. 

The research covers the current market size of the Global Blood Banking market and its growth rates based on 5 year history data along with company profile of key players/manufacturers. The in-depth information by segments of Blood Banking market helps monitor future profitability & to make critical decisions for growth. The information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the Global Blood Banking Market. 

The study provides company profiling, product picture and specifications, sales, market share and contact information of key manufacturers of Global Blood Banking Market, some of them listed here are Abbott Laboratories (USA), American Red Cross (USA), Americas Blood Centers (USA), Beckman Coulter, Inc. (USA), Becton, Dickinson and Company (USA), Bio Products Laboratory Ltd. (UK), Bio-Rad Laboratories, Inc. (USA), bioMrieux SA (France), Biotest AG (Germany), Canadian Blood Services (Canada), Cerus Corporation (USA), China Biologic Products, Inc. (China), CSL Behring LLC (USA), Fenwal Inc. (USA), Fresenius Kabi AG (Germany), Grifols S.A. (Spain), Haemonetics Corporation (USA), Huanlan Biological Engineering Inc. (China), Immucor Inc. (USA), Japan Red Cross Society (Japan), Kawasumi Laboratories, Inc. (Japan), Kedrion S.p.A. (Italy), MacoPharma SA (France), New York Blood Center (USA), Octapharma AG (Switzerland), Ortho-Clinical Diagnostics, Inc. (USA), Shanghai RAAS Blood Products Co., Ltd. (China), Shire plc (Ireland), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China) & Terumo BCT Inc. (USA). The market is growing at a very rapid pace and with rise in technological innovation, competition and M&A activities in the industry many local and regional vendors are offering specific application products for varied end-users. The new manufacturer entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology. 

Global Blood Banking (Thousands Units) and Revenue (Million USD) Market Split by Product Type such as by Blood Components & by Equipments. Further the research study is segmented by Application such as Hospitals & Blood Center with historical and projected market share and compounded annual growth rate. 
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Blood Banking in these regions, from 2012 to 2022 (forecast), covering United States, EU, Japan, China, India & Southeast Asia and its Share (%) and CAGR for the forecasted period 2017 to 2022. 

Read Detailed Index of full Research Study at @ www.htfmarketreport.com/reports/883690-global-blood-banki... 

There are 15 Chapters to display the Global Blood Banking market. 

Chapter 1, to describe Definition, Specifications and Classification of Blood Banking, Applications of Blood Banking, Market Segment by Regions; 
Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; 
Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Blood Banking, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; 
Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); 
Chapter 5 and 6, to show the Regional Market Analysis that includes United States, EU, Japan, China, India & Southeast Asia, Blood Banking Segment Market Analysis (by Type); 
Chapter 7 and 8, to analyze the Blood Banking Segment Market Analysis (by Application) Major Manufacturers Analysis of Blood Banking; 
Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type [by Blood Components & by Equipments], Market Trend by Application [Hospitals & Blood Center]; 
Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; 
Chapter 11, to analyze the Consumers Analysis of Global Blood Banking; 
Chapter 12,13, 14 and 15, to describe Blood Banking sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source. 

Check for discount @ www.htfmarketreport.com/request-discount/883690-global-bl... 

What this Research Study Offers: 

Global Blood Banking Market share assessments for the regional and country level segments
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market forecasts for a minimum of 5 years of all the mentioned segments, sub segments and the regional markets
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) 
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

About Author: 
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US : 
Craig Francis (PR & Marketing Manager) 
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

ASBP’s Low Titer Type O Whole Blood Helps Save Lives On The Battlefield

The Armed Services Blood Program is working with the Army’s 75th Ranger Regiment to bring low titer type O whole blood farther forward and closer to the point of injury. According to Army Lt. Col. Ethan Miles, 75th Ranger Regiment surgeon, it’s a blood product that could save more lives on the battlefield. 

“Historically, we have done very well treating preventable death at the point of injury. This program aims to treat hemorrhagic shock which is the leading cause of potentially survivable death on the battlefield,” Miles said. “By enabling our medics to have a practical way to administer whole blood at the point of injury, we seek to extend the period of survivability for non-compressible hemorrhage enabling successful transport to definitive surgical care.” 

The low titer type O whole blood program is different than a normal type O donation. Donors for this program are group O donors prescreened for IgM antibodies to group A and group B blood. If the levels come back at less than 1:256, the donor is considered “O low titer.” Donors are also prescreened for infectious disease. Once they are cleared, their blood is considered universal and safe to be transfused to anyone regardless of the injured patient’s blood type. 

“By pre-identifying these individuals, we greatly increase the speed and safety for performing blood transfusions far forward in the combat environment,” Miles said. “Once cleared, they serve as a walking blood bank on target, thus enabling us to draw blood from within the assault force.” 

In addition to the prescreening process, low titer type O whole blood is also not separated into three components as a regular blood donation would be. 

“The program is a way to provide a more efficacious blood product far forward on the battlefield,” said Army Lt. Col. Jason Corley, deputy director of the Army Blood Program. “So we don’t have to bring forward three different bags for three different components — red blood cells, plasma and platelets. We can give a patient at the point of injury what they need all in one bag.” 

“Given the logistical constraints with providing frozen plasma and platelet components, whole blood can be stored in a standard refrigerator and used at all roles of care. A whole blood unit is often the only source of platelets for forward surgical teams or in pre-hospital settings,” said Army Col. Audra Taylor, director of the Army Blood Program.

The Army Blood Program prescreened the first Ranger Regiment donors in May 2015. Several months later, elements of the Ranger Regiment deployed and were able to use prescreened low titer O donors to support combat operations. 

While deployed, Dr. Miles coordinated with the theater blood program to utilize low titer O whole blood collected and manufactured in the United States, and shipped around the world using military airlift. Shipping in this whole blood product helped to greatly expand the available inventory to deployed Rangers.

The program has been growing ever since. In just 18 months, the program went from concept to implementation. The Armed Services Blood Bank Center-Pacific Northwest at Joint Base Lewis-McChord, Washington, sent the first shipment of low titer type O whole blood to Afghanistan in March 2016. 

“Since then, we’ve provided over 1,000 units to CENTCOM,” Taylor said. “We are also expanding the program to make it a tri-service endeavor. With more donor centers collecting and producing this product, we are able to make sure that our service members downrange have the products they need when they need it the most.” 

The Keesler Air Force Base Blood Donor Center and two additional Army Blood Donor Centers recently started manufacturing and shipping low titer O whole blood. The Navy Blood Program will be making the product within another month.

According to Corley, the Navy and Air Force blood programs are also working with their special operations communities to develop donor prescreening procedures. The goal is to develop processes which are very similar across the services so that all donors will be prescreened to the same standard. 

“This is a great product that will certainly help save lives of our service members,” said Navy Capt. Roland Fahie, director of the Armed Services Blood Program. “By expanding this program and making it a true tri-service effort, we are able to increase the amount of low titer type O whole blood we are producing which, of course, equates to more lives saved.” 

In addition to manufacturing more of the blood product in the United States, Miles said the program is already spreading throughout the U.S. Special Operations Command and the Department of Defense. 

“Next up for the O-low titer blood use is the medevac system,” he said. “Recently, the medevac Vampire system guidelines have been updated to include the use of whole blood. We are also seeing increased use and demand by surgical teams. As more medical providers switch over to whole blood, the availability will increase while waste decreases.” 

In March, the 75th Ranger Regiment’s Ranger O Low Titer Whole Blood Program was recognized by the Army Material Command as the winner of the Army’s Greatest Innovation Award. 

“It is a true honor to receive an award like this, although nothing compares to knowing we are providing the best care possible to Rangers every day,” Miles said. “Most importantly it brings highlight to saving lives on the battlefield and furthers the support for whole blood forward. Our nation’s wars are still ongoing and we are putting our Soldiers, Sailors, Airmen and Marines in harm’s way every night. We owe them the best care possible and this is one way we can do that.”

“None of this would be getting done if it hadn’t been for the Rangers initially pushing this idea on whole blood use,” Corley said. “Big credit goes to Dr. Andre Cap and his team for being the research and technical push and support behind all of this. They came up with the ideas and the Army Blood Program just helped to operationalize it.” 

According to Miles, while the award was a great honor the most important aspect of the program is the ability to save lives of injured service members deployed downrange. Fahie credits the researchers, doctors, medics and command leadership for making it possible. 

“This program is also an example of what can happen when a military unit puts emphasis on the importance of combat casualty care,” Miles continued. “The 75th Ranger Regiment has historically placed medical as a top priority and continues to do so today. With this backing and support, we have been given the freedom and ability to pursue excellence in the field and I believe this will pay off for generations to come both inside and outside of the 75th Ranger Regiment.” 

About the Armed Services Blood Program
Since 1962, the Armed Services Blood Program has served as the sole provider of blood for the United States military. As a tri-service organization, the ASBP collects, processes, stores and distributes blood and blood products to Soldiers, Sailors, Airmen, Marines and their families worldwide. As one of four national blood collection organizations trusted to ensure the nation has a safe, potent blood supply, the ASBP works closely with our civilian counterparts by sharing donors on military installations where there are no military blood collection centers and by sharing blood products in times of need to maximize availability of this national treasure. To find out more about the ASBP or to schedule an appointment to donate, please visit www.militaryblood.dod.mil. To interact directly with ASBP staff members, see more photos or get the latest news, follow @militaryblood on Facebook, Twitter, Flickr, YouTube and Pinterest. Find the drop. Donate.

The Armed Services Blood Program is a proud recipient of the Army Maj. Gen. Keith L. Ware Public Affairs award for journalism.